CM
RVNC

Crestline Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Crestline Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-25,000
Closed -$520K – 171
2017
Q1 		$520K Buy
+25,000
New +$514K 0.1% 84

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Crestline Management's RVNC Position: Q2 2017 in Review

Crestline Management sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2017, closing a stake of 25,000 shares — an estimated $520K sold.

Crestline Management first reported a position in RVNC in Q1 2017 and held it in 1 quarter. The position peaked at $520K in Q1 2017. 86 funds tracked by Wall St. Rank hold RVNC as of Q2 2017.

  • Crestline Management reported no remaining Revance Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Crestline Management sold 25,000 Revance Therapeutics, Inc. shares in Q2 2017, an estimated $520K.
  • Crestline Management first reported a position in Revance Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
  • Crestline Management's Revance Therapeutics, Inc. position peaked at $520K in Q1 2017.
  • 86 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2017.

Based on Crestline Management's 13F filing for Q2 2017, filed 14 Aug 2017.